OrthoPediatrics Corp. filings document the regulatory record of a Nasdaq-listed medical device company focused on pediatric orthopedics. Its Form 8-K reports include quarterly and annual results, unaudited financial statements, revenue trends across Trauma and Deformity, Scoliosis, Sports Medicine/Other and OrthoPediatrics Specialty Bracing, as well as management guidance and investor presentation materials furnished under Regulation FD.
The company’s filings also cover governance and ownership matters through proxy statements, including board elections, executive compensation and equity awards. Material-event filings describe financing arrangements such as amendments to credit agreements and delayed draw term loan capacity, tying capital structure disclosures to the company’s operating and liquidity needs.
OrthoPediatrics Corp General Counsel and Secretary Daniel J. Gerritzen transferred 2,479 shares of Common Stock as a bona fide gift. The shares were given without receiving any payment. After the gift, he directly holds 147,054 shares, which the disclosure states include 121,054 restricted stock awards.
OrthoPediatrics Corp. reported first-quarter 2026 net revenue of $59.4 million, up 13% from $52.4 million a year earlier, driven by growth in trauma and deformity, scoliosis and specialty bracing across U.S. and international markets. Gross margin remained strong at 73%.
The company posted a net loss of $10.7 million, similar to the prior-year loss of $10.7 million, with loss per share of $0.45. Operating cash outflow improved to $3.3 million, and cash, restricted cash and short-term investments totaled about $50.9 million. Total debt was $106.7 million, including term loans and a 4.75% convertible note, and OrthoPediatrics added a new $20 million delayed draw term loan facility to expand future liquidity while continuing clinic acquisitions that increased goodwill to $115.2 million.
OrthoPediatrics Corp. furnished an investor presentation outlining recent performance and 2026 outlook. The company reported 2025 revenue of $236.3 million, up from $204.7 million in 2024, with a net loss of $39.6 million and diluted EPS of ($1.69). First-quarter 2026 revenue was $59.4 million versus $52.4 million a year earlier, while Adjusted EBITDA improved to $2.2 million from a slight loss. The business continues to post strong growth in trauma, deformity and scoliosis product families, supported by more than 85 pediatric systems and broad global distribution. As of March 31, 2026, the company held $50.9 million in cash, cash equivalents and short-term investments. For 2026, management guides revenue to $263.0–$267.0 million, Adjusted EBITDA of about $25.0 million and free cash flow breakeven.
OrthoPediatrics Corp. furnished an investor presentation outlining recent performance and 2026 outlook. The company reported 2025 revenue of $236.3 million, up from $204.7 million in 2024, with a net loss of $39.6 million and diluted EPS of ($1.69). First-quarter 2026 revenue was $59.4 million versus $52.4 million a year earlier, while Adjusted EBITDA improved to $2.2 million from a slight loss. The business continues to post strong growth in trauma, deformity and scoliosis product families, supported by more than 85 pediatric systems and broad global distribution. As of March 31, 2026, the company held $50.9 million in cash, cash equivalents and short-term investments. For 2026, management guides revenue to $263.0–$267.0 million, Adjusted EBITDA of about $25.0 million and free cash flow breakeven.
OrthoPediatrics Corp. reported strong first quarter 2026 results, combining double‑digit growth with improved profitability metrics. Revenue reached $59.4 million, up 13% from $52.4 million a year earlier, driven by 14% growth in Trauma & Deformity products and 13% growth in Scoliosis. U.S. revenue rose 11% to $45.3 million, while international revenue grew 22% to $14.1 million, with gross margin steady at 73%.
Operating loss narrowed to $8.3 million, and although net loss was $10.7 million, roughly flat year over year, adjusted EBITDA improved to a positive $2.2 million from a $0.4 million loss. Free cash flow usage improved to $5.0 million from $8.4 million, helped by higher adjusted EBITDA and better working capital. The company raised its 2026 revenue outlook to a range of $263.0 million to $267.0 million, implying 11% to 13% growth, and reiterated expectations for about $25.0 million of adjusted EBITDA and breakeven free cash flow for the full year.
OrthoPediatrics Corp. reported strong first quarter 2026 results, combining double‑digit growth with improved profitability metrics. Revenue reached $59.4 million, up 13% from $52.4 million a year earlier, driven by 14% growth in Trauma & Deformity products and 13% growth in Scoliosis. U.S. revenue rose 11% to $45.3 million, while international revenue grew 22% to $14.1 million, with gross margin steady at 73%.
Operating loss narrowed to $8.3 million, and although net loss was $10.7 million, roughly flat year over year, adjusted EBITDA improved to a positive $2.2 million from a $0.4 million loss. Free cash flow usage improved to $5.0 million from $8.4 million, helped by higher adjusted EBITDA and better working capital. The company raised its 2026 revenue outlook to a range of $263.0 million to $267.0 million, implying 11% to 13% growth, and reiterated expectations for about $25.0 million of adjusted EBITDA and breakeven free cash flow for the full year.
OrthoPediatrics Corp. reports continued clinical and financial progress in 2025, driven by product launches and geographic expansion. Full-year 2025 revenue reached $236.3 million, up 15% year-over-year, and the Company generated $10 million of free cash flow in Q4 2025 while reducing annual free cash flow usage by over 60% versus 2024. Management provided 2026 guidance of $262 million to $266 million in revenue (an 11–13% increase vs. 2025) and approximately $25 million of Adjusted EBITDA. The company highlights multiple product initiatives including the 3P pediatric plating platform, VerteGlide and eLLi Active Growing Implants, expanded OPSB specialty bracing, EU MDR/UK certifications and several acquisitions and clinic integrations that expand commercial reach.
OrthoPediatrics Corp. has called its 2026 annual meeting for June 4 to elect four directors, hold advisory votes on executive pay and auditor appointment, and approve an amendment to its 2024 Incentive Award Plan. As of April 6, 2026, 25,686,214 common shares were outstanding, each with one vote. The proxy details board structure, committee independence, social impact focus, and a pay program where 2025 bonuses for named executives paid out at 78.2% of target and long-term incentives were delivered in time-vested restricted stock.
OrthoPediatrics Corp. amended its existing term loan agreement to add a new delayed draw term loan facility of up to $20.0 million. Subject to conditions in the amendment, the company may draw this in minimum $10.0 million increments until June 30, 2027, allowing it to access capital as needed.
The facility carries interest at the SOFR Interest Rate with a 3.25% floor plus 6.50%, with an option for a 1.00% payment-in-kind component, and interest-only payments until the August 5, 2029 maturity. OrthoPediatrics will pay a 1.00% upfront fee and a 0.05% per annum delayed draw ticking fee, along with exit and prepayment fees consistent with the existing agreement.
ORTHOPEDIATRICS CORP executive Joseph W. Hauser reported a stock grant and related tax sale. He acquired 65,700 shares of Common Stock on March 15, 2026 as a grant at $0.00 per share, increasing his direct holdings to 203,363 shares.
On March 16, 2026, 8,596 shares were sold at $17.25 per share to satisfy tax withholding obligations upon vesting of restricted shares. After these transactions, he directly owned 194,767 shares of Common Stock, including restricted stock awards totaling 155,805 shares.
OrthoPediatrics Corp executive Fred Hite, the COO and CFO, reported both a stock grant and a related share sale. On March 15, 2026, he acquired 77,405 shares of Common Stock as a grant at $0.00 per share. On March 16, 2026, he sold 12,993 shares of Common Stock at $17.25 per share to satisfy tax withholding obligations upon vesting of restricted shares.
After these transactions, Hite directly owned 277,477 shares of OrthoPediatrics Common Stock, which the disclosure states includes restricted stock awards totaling 197,765 shares.
OrthoPediatrics Corp President and CEO David R. Bailey reported an open-market sale of 19,535 shares of common stock at $17.25 per share. According to the disclosure, these shares were sold to satisfy tax withholding obligations triggered when restricted stock vested, rather than as a discretionary portfolio move.
After this transaction, Bailey directly holds 298,020 shares of OrthoPediatrics common stock, which includes 187,891 shares of restricted stock awards. The sale represents only a portion of his overall equity position in the company.